Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 00:54 | 2023-09-29 | CBAY | N/A | EMSTER KURT VON | Director | Other | OPT+S | $15.68 | 15,921 | $249,675 | 90,000 | -15.0% |
| 2023-04-14 23:19 | 2023-04-13 | JSPR | Jasper Therapeutics, Inc. | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $1.49 | 9,075 | $13,524 | 21,175 | -30.0% |
| 2021-05-19 03:10 | 2021-05-17 | VERA | Vera Therapeutics, Inc. | EMSTER KURT VON | Director | Pharmaceutical Preparations | BUY | $11.02 | 790,555 | $8,714,683 | 2,960,231 | +36.4% |
| 2020-06-18 23:09 | 2020-06-16 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 12,500 | $200,000 | 4,168,718 | +0.3% |
| 2019-01-19 00:32 | 2018-12-18 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $29.70 | 62,925 | $1,869,168 | 1,171,268 | -5.1% |
| 2018-12-20 00:22 | 2018-12-17 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $29.85 | 72,934 | $2,176,898 | 1,164,268 | -5.9% |
| 2018-12-20 00:18 | 2018-12-17 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $7.89 | 142,381 | $1,123,585 | 131,036 | -52.1% |
| 2018-06-07 23:36 | 2018-06-05 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $12.51 | 920 | $11,509 | 18,316 | -4.8% |
| 2018-06-08 02:30 | 2018-06-05 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.51 | 920 | $11,509 | 18,316 | -4.8% |
| 2018-05-16 03:04 | 2018-05-11 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $54.39 | 650,000 | $35,352,460 | 1,237,202 | -34.4% |
| 2018-03-08 00:19 | 2018-03-05 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $15.51 | 13,353 | $207,105 | 273,417 | -4.7% |
| 2018-02-21 00:08 | 2018-02-15 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $14.49 | 68,712 | $995,637 | 286,770 | -19.3% |
| 2018-02-16 22:44 | 2018-02-14 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $13.69 | 162,979 | $2,231,183 | 355,482 | -31.4% |
| 2018-02-16 00:12 | 2018-02-13 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $15.89 | 218,057 | $3,464,228 | 355,482 | -38.0% |
| 2018-02-13 00:09 | 2017-07-19 | CBAY | N/A | EMSTER KURT VON | Director | Other | BUY | $6.50 | 153,846 | $999,999 | 1,753,846 | +9.6% |
| 2018-02-10 00:17 | 2018-02-07 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.35 | 40,763 | $503,423 | 419,693 | -8.9% |
| 2018-02-08 00:20 | 2018-02-05 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.14 | 18,831 | $228,608 | 460,456 | -3.9% |
| 2018-02-06 00:07 | 2018-02-01 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.15 | 90,098 | $1,094,610 | 479,287 | -15.8% |
| 2018-02-02 00:29 | 2018-01-30 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.22 | 97,639 | $1,193,276 | 569,385 | -14.6% |
| 2018-01-27 04:40 | 2018-01-25 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $12.18 | 39,438 | $480,355 | 667,024 | -5.6% |
| 2018-01-25 00:02 | 2018-01-22 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $10.40 | 138,253 | $1,437,831 | 706,462 | -16.4% |
| 2018-01-23 01:26 | 2018-01-18 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $10.25 | 144,216 | $1,477,666 | 844,715 | -14.6% |
| 2018-01-12 05:00 | 2018-01-05 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | BUY | $22.75 | 65,934 | $1,499,999 | 1,887,202 | +3.6% |
| 2018-01-10 00:39 | 2018-01-05 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $26.96 | 92,337 | $2,489,406 | 1,821,268 | -4.8% |
| 2018-01-10 00:34 | 2018-01-05 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $10.21 | 4,300 | $43,903 | 988,931 | -0.4% |
| 2018-01-05 01:29 | 2018-01-02 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $26.76 | 37,754 | $1,010,123 | 1,913,605 | -1.9% |
| 2017-12-28 00:08 | 2017-12-22 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $9.41 | 173,192 | $1,629,304 | 993,231 | -14.8% |
| 2017-11-15 01:48 | 2017-11-10 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $9.26 | 50,048 | $463,379 | 1,166,423 | -4.1% |
| 2017-11-03 23:52 | 2017-11-01 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $9.25 | 4,320 | $39,979 | 1,216,471 | -0.4% |
| 2017-11-01 23:39 | 2017-10-30 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $9.27 | 59,209 | $548,802 | 1,220,791 | -4.6% |
| 2017-10-04 23:02 | 2017-10-02 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $7.85 | 108,876 | $854,873 | 1,280,000 | -7.8% |
| 2017-10-03 00:20 | 2017-09-28 | CBAY | N/A | EMSTER KURT VON | Director | Other | SALE | $8.09 | 211,124 | $1,707,381 | 1,388,876 | -13.2% |
| 2017-08-30 23:18 | 2017-08-28 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $19.79 | 88,011 | $1,741,738 | 1,951,359 | -4.3% |
| 2017-08-28 23:33 | 2017-08-24 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $19.42 | 22,781 | $442,402 | 2,039,370 | -1.1% |
| 2017-08-24 23:02 | 2017-08-22 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $18.53 | 17,989 | $333,336 | 2,062,151 | -0.9% |
| 2017-08-22 23:02 | 2017-08-18 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $18.52 | 3,150 | $58,345 | 2,080,140 | -0.2% |
| 2017-08-18 23:16 | 2017-08-16 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $19.06 | 34,141 | $650,693 | 2,083,290 | -1.6% |
| 2017-08-16 23:14 | 2017-08-14 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $19.59 | 55,569 | $1,088,563 | 2,117,431 | -2.6% |
| 2017-08-09 23:12 | 2017-08-07 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $18.63 | 35,473 | $660,887 | 2,190,872 | -1.6% |
| 2017-08-07 23:18 | 2017-08-03 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $17.81 | 50,477 | $899,217 | 2,226,345 | -2.2% |
| 2017-08-02 23:21 | 2017-07-31 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $17.51 | 5,512 | $96,491 | 2,276,822 | -0.2% |
| 2017-07-31 23:07 | 2017-07-27 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $17.63 | 41,312 | $728,132 | 2,282,334 | -1.8% |
| 2017-07-27 23:51 | 2017-07-25 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $17.60 | 32,930 | $579,545 | 2,323,646 | -1.4% |
| 2017-07-17 23:11 | 2017-07-13 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $16.84 | 69,859 | $1,176,712 | 2,356,576 | -2.9% |
| 2017-07-13 23:00 | 2017-07-11 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $16.56 | 31,992 | $529,938 | 2,408,563 | -1.3% |
| 2017-07-07 23:24 | 2017-07-05 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $16.26 | 4,254 | $69,170 | 2,440,555 | -0.2% |
| 2017-06-30 23:50 | 2017-06-28 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $16.90 | 43,202 | $730,127 | 2,444,809 | -1.7% |
| 2017-06-28 23:05 | 2017-06-26 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $17.08 | 81,435 | $1,390,608 | 2,488,011 | -3.2% |
| 2017-06-26 23:39 | 2017-06-22 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | SALE | $16.23 | 32,368 | $525,304 | 2,569,446 | -1.2% |
| 2017-02-11 03:23 | 2016-10-24 | CRSP | CRISPR Therapeutics AG | EMSTER KURT VON | Director | Biological Products, (No Diagnostic Substances) | BUY | $14.00 | 56,000 | $784,000 | 2,601,814 | +2.2% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.